# Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

> **NCT02182245** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Genital Neoplasms, Female

## Interventions

- **DRUG:** BIBF 1120
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02182245
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-01
- **Primary completion:** 2007-01-01
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182245, "Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02182245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*